Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
ObjectiveThis study mainly observes the efficacy and safety of almonertinib plus chemotherapy compared with almonertinib alone in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR).MethodsIn this study, clinical data of 68 pa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1248690/full |
| _version_ | 1797688798344118272 |
|---|---|
| author | Xiaoxu Fang Yan Xiang Kaihua Lu |
| author_facet | Xiaoxu Fang Yan Xiang Kaihua Lu |
| author_sort | Xiaoxu Fang |
| collection | DOAJ |
| description | ObjectiveThis study mainly observes the efficacy and safety of almonertinib plus chemotherapy compared with almonertinib alone in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR).MethodsIn this study, clinical data of 68 patients with advanced NSCLC who were treated in Jiangsu Provincial People’s Hospital and Nanjing Chest Hospital between April 2020 and December 2022 were collected. Among them, the study group (n=30) received second-line almonertinib combined with platinum-based chemotherapy, while the control group (n=38) received almonertinib alone. The near-term and long-term effects and adverse events of the two groups were compared respectively.ResultsThe median follow-up time until 31 December 2022 was 16.3 months (95% CI: 11.32-21.34). Results of chi-square analysis showed no statistically significant difference in objective response rate (ORR) and disease control rate (DCR) between the study group and the control group (56.73% vs. 55.3%, P>0.05; 100% vs. 86.8%, P>0.05). Log-rank test comparing the two groups revealed that the median progression-free survival (mPFS) of the study group was significantly longer than that of the control group by 3.1 months (12.7 vs. 9.6 months, P=0.01). Multivariate COX proportional risk model showed a statistically significant effect of treatment method and PS score on PFS (HR=0.43, P=0.023; HR=3.82, P=0.001). In terms of safety, most of the adverse events (AEs) were mild, with no grade 4-5 in the two groups, and the overall tolerance of patients was good.ConclusionFor advanced NSCLC patients with EGFR mutations, second-line treatment with almonertinib plus chemotherapy significantly improved PFS compared with almonertinib alone without a significant increase in adverse events, providing efficacy and safety. |
| first_indexed | 2024-03-12T01:36:54Z |
| format | Article |
| id | doaj.art-1e3637fda7654c469ec4418b76364cc6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T01:36:54Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1e3637fda7654c469ec4418b76364cc62023-09-11T05:59:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.12486901248690Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective studyXiaoxu FangYan XiangKaihua LuObjectiveThis study mainly observes the efficacy and safety of almonertinib plus chemotherapy compared with almonertinib alone in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR).MethodsIn this study, clinical data of 68 patients with advanced NSCLC who were treated in Jiangsu Provincial People’s Hospital and Nanjing Chest Hospital between April 2020 and December 2022 were collected. Among them, the study group (n=30) received second-line almonertinib combined with platinum-based chemotherapy, while the control group (n=38) received almonertinib alone. The near-term and long-term effects and adverse events of the two groups were compared respectively.ResultsThe median follow-up time until 31 December 2022 was 16.3 months (95% CI: 11.32-21.34). Results of chi-square analysis showed no statistically significant difference in objective response rate (ORR) and disease control rate (DCR) between the study group and the control group (56.73% vs. 55.3%, P>0.05; 100% vs. 86.8%, P>0.05). Log-rank test comparing the two groups revealed that the median progression-free survival (mPFS) of the study group was significantly longer than that of the control group by 3.1 months (12.7 vs. 9.6 months, P=0.01). Multivariate COX proportional risk model showed a statistically significant effect of treatment method and PS score on PFS (HR=0.43, P=0.023; HR=3.82, P=0.001). In terms of safety, most of the adverse events (AEs) were mild, with no grade 4-5 in the two groups, and the overall tolerance of patients was good.ConclusionFor advanced NSCLC patients with EGFR mutations, second-line treatment with almonertinib plus chemotherapy significantly improved PFS compared with almonertinib alone without a significant increase in adverse events, providing efficacy and safety.https://www.frontiersin.org/articles/10.3389/fonc.2023.1248690/fullalmonertinibnon-small cell lung cancerepidermal growth factor receptor mutationchemotherapysafety |
| spellingShingle | Xiaoxu Fang Yan Xiang Kaihua Lu Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study Frontiers in Oncology almonertinib non-small cell lung cancer epidermal growth factor receptor mutation chemotherapy safety |
| title | Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study |
| title_full | Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study |
| title_fullStr | Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study |
| title_full_unstemmed | Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study |
| title_short | Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study |
| title_sort | almonertinib plus chemotherapy versus almonertinib alone in second line treatment of advanced non small cell lung cancer with mutated epidermal growth factor receptor a retrospective study |
| topic | almonertinib non-small cell lung cancer epidermal growth factor receptor mutation chemotherapy safety |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1248690/full |
| work_keys_str_mv | AT xiaoxufang almonertinibpluschemotherapyversusalmonertinibaloneinsecondlinetreatmentofadvancednonsmallcelllungcancerwithmutatedepidermalgrowthfactorreceptoraretrospectivestudy AT yanxiang almonertinibpluschemotherapyversusalmonertinibaloneinsecondlinetreatmentofadvancednonsmallcelllungcancerwithmutatedepidermalgrowthfactorreceptoraretrospectivestudy AT kaihualu almonertinibpluschemotherapyversusalmonertinibaloneinsecondlinetreatmentofadvancednonsmallcelllungcancerwithmutatedepidermalgrowthfactorreceptoraretrospectivestudy |